Prediction of Thiopurine Metabolite Levels Based on Haematological and Biochemical Parameters
Language English Country United States Media print
Document type Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
31568041
DOI
10.1097/mpg.0000000000002436
PII: 00005176-201910000-00018
Knihovny.cz E-resources
- MeSH
- Medication Adherence * MeSH
- Models, Biological MeSH
- Child MeSH
- Erythrocytes metabolism MeSH
- Inflammatory Bowel Diseases blood drug therapy metabolism MeSH
- Immunosuppressive Agents administration & dosage pharmacokinetics therapeutic use MeSH
- Humans MeSH
- Mercaptopurine administration & dosage analogs & derivatives pharmacokinetics therapeutic use MeSH
- Adolescent MeSH
- Drug Monitoring MeSH
- Area Under Curve MeSH
- Predictive Value of Tests MeSH
- Sensitivity and Specificity MeSH
- Thioguanine metabolism MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Evaluation Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- azathiopurine MeSH Browser
- Immunosuppressive Agents MeSH
- Mercaptopurine MeSH
- Thioguanine MeSH
OBJECTIVES: Therapeutic drug monitoring of thiopurine erythrocyte levels is not available in all centers and it usually requires quite a long time to obtain the results. The aims of this study were to build a model predicting low levels of 6-thioguanine and 6-methylmercaptopurine in pediatric inflammatory bowel disease (IBD) patients and to build a model to predict nonadherence in patients treated with azathioprine (AZA). METHODS: The study consisted of 332 observations in 88 pediatric IBD patients. Low AZA dosing was defined as 6-thioguanine levels <125 pmol/8 × 10 erythrocytes and 6-methylmercaptopurine levels <5700 pmol/8 × 10 erythrocytes. Nonadherence was defined as undetectable levels of 6-thioguanine and 6-methylmercaptopurine <240 pmol/8 × 10 erythrocytes. Data were divided into training and testing part. To construct the model predicting low 6-thioguanine levels, nonadherence, and the level of 6-thioguanine, the modification of random forest method with cross-validation and resampling was used. RESULTS: The final models predicting low 6-thioguanine levels and nonadherence had area under the curve, 0.87 and 0.94; sensitivity, 0.81 and 0.82; specificity, 0.80 and 86; and distance, 0.31 and 0.21, respectively, when applied on the testing part of the dataset. When the final model for prediction of 6-thioguanine values was applied on testing dataset, a root-mean-square error of 110 was obtained. CONCLUSIONS: Using easily obtained laboratory parameters, we constructed a model with sufficient accuracy to predict patients with low 6-thioguanine levels and a model for prediction of AZA treatment nonadherence (web applications: https://hradskyo.shinyapps.io/6TG_prediction/ and https://hradskyo.shinyapps.io/Non_adherence/).
References provided by Crossref.org